Best Practices in Immunotherapy – June/July 2017 Vol 8

Best Practices in immunotherapy - June/July 2017 Vol 8

Letters from Lillie

Immunotherapy— A Powerful Tool in the Fight Against Cancer

Lillie D. Shockney, RN, BS, MAS, ONN-CG 

Dear Navigators, On behalf of the JONS Editorial Board, it is my pleasure to present this special edition dedicated to the topic of immunotherapy. One of the many responsibilities of [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Combination Immunotherapy Helps Heavily Pretreated Melanoma Patients

A new study has shown that combination immunotherapy can yield significant clinical benefits—even in heavily pretreated populations. According to data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, administration of [ Read More ]

FDA Updates

Pembrolizumab Approved as First Cancer Treatment Based on Biomarkers

The FDA has granted accelerated approval to pembrolizumab for the treatment of any solid tumor in the body with a specific genetic feature, or biomarker. Until now, FDA approval for [ Read More ]

Immune Checkpoint Inhibitors

Who’s a Candidate for Immune Checkpoint Inhibitors?

The production of antibodies is the immune system’s way of waging an attack on something threatening. Monoclonal antibodies can be designed as immunotherapies that will attach to specific proteins on [ Read More ]

Melanoma

Talimogene Laherparepvec (T-VEC) as Cancer Immunotherapy

Sachin Jhawar, MD
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ


Sharad Goyal, MD
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ


Praveen K. Bommareddy, MS
Department of Surgery
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ

Andrew Zloza, MD, PhD
Division of Surgical Oncology Research, Section of Surgical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ

Howard L. Kaufman, MD, FACS
Department of Surgery
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ 

Dr Jhawar is a resident in the Department of Radiation Oncology at Rutgers Cancer Institute of New Jersey. His interests include radiation and its effects on tumor immunity. Dr Goyal [ Read More ]

AONN+ West Coast Regional Meeting, Immunotherapy

What Your Patient Needs to Know About Immunotherapy

 

Immunotherapy drugs are being approved for the treatment of more and more cancers and are making significant improvements in the lives of many patients. As a result, it has become [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Gut Reaction: Microbiome Linked to Anti–PD-1 Response

New research into gut bacteria may shed light on the mystery of responsiveness to immunotherapy. The multi-institutional study, presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, showed that patients with [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Vaccine Shows Strong T-Cell Response in Advanced Cervical Cancer

When combined with chemotherapy, a vaccine against the human papillomavirus type 16 (HPV16) elicited strong T-cell responsiveness and improved clinical outcomes in patients with advanced cervical cancer. According to results [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Nonengineered T-Cell Therapy Shows Promise in Multiple Cancers

The heterogeneity of malignancies has long vexed cancer researchers, but a new approach to immunotherapy may offer a solution. According to data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Optimizing Immunity in Melanoma via T-Cell Activation

With single-agent PD-1/PD-L1 therapy, melanoma patients are achieving outcomes once thought impossible for the disease, with some responses lasting more than a decade. Nevertheless, this pillar of cancer therapy is [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Intratumoral Plasmid Interleukin-12 Bolsters Pembrolizumab Response

In patients with stage III/IV melanoma, intratumoral injections of plasmid interleukin-12 (IL-12) via electroporation enhanced response to immune checkpoint blockade. According to data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Mutational Load and T-Cell–Inflamed Microenvironment May Predict Response to Pembrolizumab

The advent of immunotherapy has led to durable clinical responses in a variety of malignancies, but identifying which patients will respond to treatment remains an elusive goal. According to data [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Plinabulin Improves Survival and Duration of Response in Advanced Non–Small Cell Lung Cancer

When added to treatment with docetaxel, the investigational drug plinabulin improved overall survival by 4.7 months in patients with advanced non–small cell lung cancer (NSCLC) with measurable lesions. Data from [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Projected Long-Term Survival High for Patients with Advanced Non–Small Cell Lung Cancer Treated with Pembrolizumab

Durability of benefit—the possibility for sustained remission in patients with previously incurable disease—is already one of the hallmarks of immunotherapy. According to recent statistical analysis, however, this durability may even [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Oncolytic Virotherapy: A New Cornerstone for Immuno-Oncology

When administered by intratumoral injection, oncolytic viruses have been shown to enhance the body’s immune response and be effective in combination with checkpoint antibodies. According to data presented at the [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Avelumab Demonstrates Efficacy Across All Subgroups in Metastatic Merkel Cell Carcinoma

For patients with metastatic Merkel cell carcinoma, a rare and aggressive form of skin cancer associated with poor survival, avelumab may soon offer a new therapeutic option. According to subgroup [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

T-VEC Boosts Immunotherapy in Phase 1 Trials

A genetically modified herpesvirus appears to enhance response to immunotherapy in melanoma patients. According to preliminary data presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, when used in combination with [ Read More ]

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Beyond PD-1: Harnessing Receptor Crosstalk to Overcome Immune Escape

Immune checkpoint therapy, specifically PD-1 blockade, has improved survival for patients with metastatic cancer, but not all patients respond to treatment. At the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, Robert L. [ Read More ]

2017 Gastrointestinal Cancers Symposium

Nivolumab a New Treatment Option for Patients with Advanced Gastric Cancer

Nivolumab as salvage treatment significantly reduced the risk for death after second-line or later chemotherapy in patients with advanced gastric or gastroesophageal junction cancer. In a double-blind, randomized phase 3 [ Read More ]